Investment Rating - The report maintains a "Buy" investment rating for the company [1][8] Core Views - The company is focusing on cost reduction and efficiency improvement, leading to gradual profit enhancement and expansion of its second growth curve [1][5] - The company reported a total revenue of 689 million yuan for H1 2025, a decrease of 16% year-on-year, but showed improvement in net profit loss compared to H1 2024 [4][5] - The company is enhancing its profitability through strict cost control measures, resulting in a gross margin increase of 5 percentage points to 22.81% in Q2 2025 [5] - The company is expanding its product lines in health food and optimizing its multi-channel distribution strategy, which includes partnerships with major retailers and e-commerce platforms [6] Summary by Sections Financial Performance - In H1 2025, the company achieved a total revenue of 689 million yuan, with a net loss of 20 million yuan, an improvement from a net loss of 36 million yuan in H1 2024 [4] - Q2 2025 revenue was 276 million yuan, down 14% year-on-year, with a net loss of 60 million yuan [4] Profitability Improvement - The company's gross margin increased to 22.81% in Q2 2025, driven by targeted raw material procurement and refined production management [5] - The selling expense ratio decreased by 2 percentage points to 21.62%, and the management expense ratio also decreased by 2 percentage points to 7.55% [5] Product and Market Expansion - Revenue from red date products and health preservation products decreased by 16% and 26% respectively, but the gross margin for red date products increased by 8 percentage points to 34.60% [6] - The company is building a diversified product matrix around its core positioning as a "red date expert," with significant growth in its flagship product, Hong Xiaopai [6] Earnings Forecast - The company is expected to achieve EPS of 0.02, 0.17, and 0.27 yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 445, 62, and 39 times [8]